Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Science ; 340(6128): 82-5, 2013 Apr 05.
Article in English | MEDLINE | ID: mdl-23559250

ABSTRACT

MicroRNAs (miRNAs) control gene expression through both translational repression and degradation of target messenger RNAs (mRNAs). However, the interplay between these processes and the precise molecular mechanisms involved remain unclear. Here, we show that translational inhibition is the primary event required for mRNA degradation. Translational inhibition depends on miRNAs impairing the function of the eIF4F initiation complex. We define the RNA helicase eIF4A2 as the key factor of eIF4F through which miRNAs function. We uncover a correlation between the presence of miRNA target sites in the 3' untranslated region (3'UTR) of mRNAs and secondary structure in the 5'UTR and show that mRNAs with unstructured 5'UTRs are refractory to miRNA repression. These data support a linear model for miRNA-mediated gene regulation in which translational repression via eIF4A2 is required first, followed by mRNA destabilization.


Subject(s)
Eukaryotic Initiation Factor-4A/biosynthesis , Gene Expression Regulation , MicroRNAs/metabolism , Protein Biosynthesis , RNA Stability , RNA, Messenger/metabolism , HEK293 Cells , HeLa Cells , Humans
2.
Kidney Int ; 70(8): 1397-402, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16955109

ABSTRACT

Representatives from five international organizations (International Society of Nephrology, World Heart Federation, International Diabetes Federation, International Atherosclerosis Federation, and International Society of Hypertension) participated in a strategic planning workshop in December 2005 in Bellagio, Italy sponsored by the Rockefeller Foundation. There were equal representatives from developed and developing countries. Global perspectives on diabetes and cardiovascular and renal diseases were presented, with special emphasis on China, India, Latin America, and Africa. The rationale and effectiveness of preventive measures were discussed. It was apparent that measures for primary prevention and early intervention for all the chronic vascular diseases are similar. The five organizations agreed that an integrated global approach to chronic vascular diseases is needed. They resolved to collaborate and work towards an integrated approach to chronic vascular diseases with the establishment of a 5-year plan for the prevention and treatment of chronic vascular diseases, including public advocacy, advising international and national agencies, and improving education and the practice of established approaches.


Subject(s)
Diabetes Complications/prevention & control , Global Health , International Agencies/trends , Vascular Diseases/prevention & control , Chronic Disease , Developed Countries , Developing Countries , Diabetes Mellitus/prevention & control , Health Services Accessibility , Humans , International Cooperation , Italy , Kidney Diseases/prevention & control , Patient Advocacy , Risk Factors
3.
Biophys J ; 81(5): 2647-59, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11606278

ABSTRACT

The Na(+) current component I(Ca(TTX)) is functionally distinct from the main body of Na(+) current, I(Na). It was proposed that I(Ca(TTX)) channels are I(Na) channels that were altered by bathing media containing Ca(2+), but no, or very little, Na(+). It is known that Na(+)-free conditions are not required to demonstrate I(Ca(TTX).) We show here that Ca(2+) is also not required. Whole-cell, tetrodotoxin-blockable currents from fresh adult rat ventricular cells in 65 mm Cs(+) and no Ca(2+) were compared to those in 3 mM Ca(2+) and no Cs(+) (i.e., I(Ca(TTX))). I(Ca(TTX)) parameters were shifted to more positive voltages than those for Cs(+). The Cs(+) conductance-voltage curve slope factor (mean, -4.68 mV; range, -3.63 to -5.72 mV, eight cells) is indistinguishable from that reported for I(Ca(TTX)) (mean, -4.49 mV; range, -3.95 to -5.49 mV). Cs(+) current and I(Ca(TTX)) time courses were superimposable after accounting for the voltage shift. Inactivation time constants as functions of potential for the Cs(+) current and I(Ca(TTX)) also superimposed after voltage shifting, as did the inactivation curves. Neither of the proposed conditions for conversion of I(Na) into I(Ca(TTX)) channels is required to demonstrate I(Ca(TTX)). Moreover, we find that cardiac Na(+) (H1) channels expressed heterologously in HEK 293 cells are not converted to I(Ca(TTX)) channels by Na(+)-free, Ca(2+)-containing bathing media. The gating properties of the Na(+) current through H1 and those of Ca(2+) current through H1 are identical. All observations are consistent with two non-interconvertable Na(+) channel populations: a larger that expresses little Ca(2+) permeability and a smaller that is appreciably Ca(2+)-permeable.


Subject(s)
Calcium Channels/metabolism , Cesium/antagonists & inhibitors , Cesium/metabolism , Myocardium/metabolism , Sodium Channels/metabolism , Tetrodotoxin/pharmacology , Animals , Calcium Channels/drug effects , Cell Line/cytology , Cell Membrane/metabolism , Electrophysiology/methods , Heart Ventricles/cytology , Humans , Membrane Potentials/physiology , Myocardium/cytology , Rats , Rats, Sprague-Dawley , Rats, Wistar , Transfection/methods
4.
Annu Rev Genet ; 34: 687-745, 2000.
Article in English | MEDLINE | ID: mdl-11092843

ABSTRACT

Obesity is a health problem of epidemic proportions in the industrialized world. The cloning and characterization of the genes for the five naturally occurring monogenic obesity syndromes in the mouse have led to major breakthroughs in understanding the physiology of energy balance and the contribution of genetics to obesity in the human population. However, the regulation of energy balance is an extremely complex process, and it is quickly becoming clear that hundreds of genes are involved. In this article, we review the naturally occurring monogenic and polygenic obese mouse strains, as well as the large number of transgenic and knockout mouse models currently available for the study of obesity and energy balance.


Subject(s)
Energy Metabolism/genetics , Models, Genetic , Obesity/genetics , Animals , Genetic Predisposition to Disease , Mice , Mutation
6.
Ann Intern Med ; 132(8): 636-40, 2000 Apr 18.
Article in English | MEDLINE | ID: mdl-10766682

ABSTRACT

BACKGROUND: Coenzyme Q10 is commonly used to treat congestive heart failure on the basis of data from several unblinded, subjective studies. Few randomized, blinded, controlled studies have evaluated objective measures of cardiac performance. OBJECTIVE: To determine the effect of coenzyme Q10 on peak oxygen consumption, exercise duration, and ejection fraction. DESIGN: Randomized, double-blind, controlled trial. SETTING: University and Veterans Affairs hospitals. PATIENTS: 55 patients who had congestive heart failure with New York Heart Association class III and IV symptoms, ejection fraction less than 40%, and peak oxygen consumption less than 17.0 mL/kg per minute (or <50% of predicted) during standard therapy were randomly assigned. Forty-six patients completed the study. INTERVENTION: Coenzyme Q10, 200 mg/d, or placebo. MEASUREMENTS: Left ventricular ejection fraction (measured by radionuclide ventriculography) and peak oxygen consumption and exercise duration (measured by a graded exercise evaluation using the Naughton protocol) with continuous metabolic monitoring. RESULTS: Although the mean (+/-SD) serum concentration of coenzyme Q10 increased from 0.95+/-0.62 microg/mL to 2.2+/-1.2 microg/mL in patients who received active treatment, ejection fraction, peak oxygen consumption, and exercise duration remained unchanged in both the coenzyme Q10 and placebo groups. CONCLUSION: Coenzyme Q10 does not affect ejection fraction, peak oxygen consumption, or exercise duration in patients with congestive heart failure receiving standard medical therapy.


Subject(s)
Antioxidants/therapeutic use , Heart Failure/drug therapy , Ubiquinone/analogs & derivatives , Antioxidants/metabolism , Coenzymes , Double-Blind Method , Exercise Tolerance , Female , Heart Failure/enzymology , Heart Failure/physiopathology , Humans , Male , Middle Aged , Oxygen Consumption , Placebos , Radionuclide Ventriculography , Stroke Volume , Ubiquinone/blood , Ubiquinone/therapeutic use
7.
J Neurosci ; 19(14): 5889-97, 1999 Jul 15.
Article in English | MEDLINE | ID: mdl-10407028

ABSTRACT

One of two orphan photoreceptor guanylyl cyclases that are highly conserved from fish to mammals, GC-E (or retGC1) was eliminated by gene disruption. Expression of the second retinal cyclase (GC-F) as well as the numbers and morphology of rods remained unchanged in GC-E null mice. However, rods isolated from such mice, despite having a normal dark current, recovered from a light flash markedly faster. Unexpectedly, the a- and b-waves of electroretinograms (ERG) from dark-adapted null mice were suppressed markedly. Cones, initially present in normal numbers in the retina, disappeared by 5 weeks, based on ERG and histology. Thus, the GC-E-deficient mouse defines a model for cone dystrophy, but it also demonstrates that morphologically normal rods display paradoxical behavior in their responses to light.


Subject(s)
Guanylate Cyclase/genetics , Guanylate Cyclase/metabolism , Retina/enzymology , Retinal Cone Photoreceptor Cells/physiology , Retinal Rod Photoreceptor Cells/physiology , Retinitis Pigmentosa/genetics , Adaptation, Ocular , Animals , Darkness , Electroretinography , Exons , Guanylate Cyclase/deficiency , Mice , Mice, Inbred Strains , Mice, Knockout , Restriction Mapping , Retinal Cone Photoreceptor Cells/pathology , Retinal Rod Photoreceptor Cells/pathology , Retinitis Pigmentosa/pathology , Retinitis Pigmentosa/physiopathology
9.
Hosp Pract (1995) ; 34(9): 51-6, 59-64, 1999 Sep 01.
Article in English | MEDLINE | ID: mdl-10901760

ABSTRACT

Combination therapy with a diuretic, digoxin, ACE inhibitor, and beta-blocker can help patients with heart failure caused by severe systolic dysfunction feel better and live longer. Especially with ACE inhibitors and beta-blockers, the key to success is starting at low doses and titrating carefully to proven target doses. The demanding complexity of the four-drug regimen is well worth the results.


Subject(s)
Drug Therapy, Combination , Heart Failure/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Cardiotonic Agents/therapeutic use , Digoxin/therapeutic use , Diuretics/therapeutic use , Humans
10.
Physiol Rev ; 78(1): 189-225, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9457173

ABSTRACT

The diverse physiological actions of dopamine are mediated by at least five distinct G protein-coupled receptor subtypes. Two D1-like receptor subtypes (D1 and D5) couple to the G protein Gs and activate adenylyl cyclase. The other receptor subtypes belong to the D2-like subfamily (D2, D3, and D4) and are prototypic of G protein-coupled receptors that inhibit adenylyl cyclase and activate K+ channels. The genes for the D1 and D5 receptors are intronless, but pseudogenes of the D5 exist. The D2 and D3 receptors vary in certain tissues and species as a result of alternative splicing, and the human D4 receptor gene exhibits extensive polymorphic variation. In the central nervous system, dopamine receptors are widely expressed because they are involved in the control of locomotion, cognition, emotion, and affect as well as neuroendocrine secretion. In the periphery, dopamine receptors are present more prominently in kidney, vasculature, and pituitary, where they affect mainly sodium homeostasis, vascular tone, and hormone secretion. Numerous genetic linkage analysis studies have failed so far to reveal unequivocal evidence for the involvement of one of these receptors in the etiology of various central nervous system disorders. However, targeted deletion of several of these dopamine receptor genes in mice should provide valuable information about their physiological functions.


Subject(s)
Brain/physiology , Pituitary Gland/physiology , Receptors, Dopamine/chemistry , Receptors, Dopamine/physiology , Animals , Animals, Genetically Modified , Gene Expression Regulation , Humans , Hypertension/physiopathology , Mice , Receptors, Dopamine/genetics , Signal Transduction
11.
Mol Pharmacol ; 52(3): 508-14, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9281614

ABSTRACT

Despite a great deal of research, the second messenger coupling of the dopamine D3 receptor has not yet been clearly established. The closely related D2 and D4 receptors have been shown to inhibit adenylyl cyclase activity in a variety of cell types, but the D3 receptor has little or no effect on this second messenger system. We now demonstrate that when the D3 receptor and adenylyl cyclase type V are coexpressed in 293 cells, the agonist quinpirole causes 70% inhibition of forskolin-stimulated cAMP levels. This effect seems to be selective for this adenylyl cyclase isoform because the D3 receptor does not inhibit adenylyl cyclase types I or VI and only weakly stimulates adenylyl cyclase type II. In contrast, the D2 receptor inhibits cAMP accumulation in 293 cells in the absence of cotransfected adenylyl cyclases and stimulates adenylyl cyclase type II to a greater extent than the D3 receptor. The inhibition of adenylyl cyclase type V by the D3 receptor is sensitive to pertussis toxin, suggesting the involvement of G proteins of the Gi family. Guanosine-5'-O-(3-thio)triphosphate binding studies indicate that the D3 receptor weakly activates all three Gialpha subunits, whereas the D2 receptor activates these G proteins to a substantially greater extent. However, despite its relative inability to promote G protein activation, the D3 receptor is capable of substantial and consistent inhibition of adenylyl cyclase type V. The robust second messenger coupling of the D3 receptor in a heterologous system with defined components provides a system for further studies of the function of this receptor and should facilitate the development and characterization of new D3 receptor ligands.


Subject(s)
Adenylyl Cyclase Inhibitors , Isoenzymes/antagonists & inhibitors , Receptors, Dopamine D2/physiology , Animals , Cells, Cultured , Colforsin/antagonists & inhibitors , Colforsin/pharmacology , Cyclic AMP/metabolism , Dogs , Dopamine Agonists/pharmacology , Drug Interactions , Embryo, Mammalian , Humans , Kidney/metabolism , Quinpirole/pharmacology , Rats , Receptors, Dopamine D2/genetics , Receptors, Dopamine D2/metabolism , Receptors, Dopamine D3 , Transfection
12.
J Cell Sci ; 109 ( Pt 10): 2529-37, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8923214

ABSTRACT

The endoplasmic reticulum undergoes rapid, microscopic changes in its structure, including extension and anastomosis of tubular elements. Such dynamism is expected to manifest itself also as rapid intermixing of membrane components, at least within subdomains of the endoplasmic reticulum. Here we present evidence of a similar dynamism in the sarcoplasmic reticulum of developing skeletal muscle. The sarcoplasmic reticulum is sometimes considered a specialized type of endoplasmic reticulum, but it appears to be a rather static set of membrane-bound elements, repetitively arranged to enwrap each sarcomere of each myofibril. Both endoplasmic reticulum and sarcoplasmic reticulum contain P-type Ca(2+)-ATPases that transport calcium from the cytosol into their lumen. In the experiments reported here, chicken and mouse cells were fused by polyethylene glycol, natural myogenic cell fusion, or Sendai virus. The redistribution of Ca(2+)-ATPase molecules between chick and mouse endoplasmic reticulum/sarcoplasmic reticulum was followed by immunofluorescence microscopy in which species-specific monoclonal antibodies to chick and mouse Ca(2+)-ATPases were used. Redistribution was time- and temperature-dependent but independent of protein synthesis as well as the method of cell fusion. Intermixing occurred on a time scale of tens of minutes at 37 degrees C. These results verify the dynamic nature of the sarcoplasmic reticulum and illustrate an aspect of the special relationship between endoplasmic reticulum and sarcoplasmic reticulum.


Subject(s)
Calcium-Transporting ATPases/metabolism , Muscle, Skeletal/metabolism , Sarcoplasmic Reticulum/metabolism , Animals , Cell Fusion/physiology , Cell Line , Chick Embryo , Cycloheximide/pharmacology , Fibroblasts , Fluorescent Antibody Technique, Direct , Intracellular Membranes/chemistry , Intracellular Membranes/metabolism , Mice , Muscle, Skeletal/drug effects , Sarcoplasmic Reticulum/chemistry , Temperature , Time Factors
13.
Anal Chem ; 68(15): 2621-8, 1996 Aug 01.
Article in English | MEDLINE | ID: mdl-8694261

ABSTRACT

Nitric oxide (NO.) sensors were prepared using o-phenylenediamine (o-PD) and Nafion to modify the surface of 30 microns diameter carbon fiber electrodes. These electrodes were compared with nickel porphyrin-type NO. sensors that have already been described. High-speed chronoamperometry, amperometry, and differential pulse voltammetry were used to compare the performance of sensors modified with various combinations of Nafion, o-PD, or nickel(II) meso-tetrakis(3-methoxy-4-hydroxyphenyl) porphyrin (Ni-TMPP), in order to determine which electrodes had the most sensitivity and selectivity for NO. Our findings showed that electrodes treated with Nafion first, followed by o-PD, were very sensitive to NO., with a detection limit of 35 +/- 7 nM. In addition, o-PD electrodes were also very selective against ascorbate (> 600:1), dopamine (> 300:1), and nitrite (> 900:1). Moreover, in the range of 0-6 microM NO., o-PD electrodes displayed excellent linearity (R2 > or = 0.997). In contrast, Ni-TMPP electrodes (with Nafion) had significantly poorer detection limits (76 +/- 12 nM) and were less selective against dopamine (< 5:1) and nitrite (< 200:1). Ni-TMPP electrodes were also less linear than o-PD electrodes (R2 > or = 0.911). Finally, we tested the in vitro and in vivo performance of the o-PD electrode in terms of its ability to detect NO. release from isolated rat renal arterioles and to measure NO. diffusion in the extracellular space of the rat brain.


Subject(s)
Nitric Oxide/analysis , Animals , Calibration , Electrodes , Fluorocarbon Polymers/pharmacology , Male , Phenylenediamines/pharmacology , Rats , Rats, Sprague-Dawley
14.
J Neurochem ; 67(1): 212-9, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8666994

ABSTRACT

Despite a high degree of sequence homology, the dopamine D2 and D3 receptors have substantially different second messenger coupling properties. We have used chimeric D2/D3 receptors to investigate the contribution of the intracellular loops to the signaling properties of these receptors. In HEK 293 cells, D2 receptors inhibit prostaglandin E1-stimulated cyclic AMP levels by >90%, whereas D3 receptors inhibit cyclic AMP accumulation by only 20%. In chimeras that have the second or third intracellular loop, or both loops simultaneously, switched between the D2 and D3 receptors, the maximal inhibition of adenylyl cyclase is 60-90%. In addition, the potency of quinpirole to inhibit adenylyl cyclase activity at some of the chimeras is altered compared with the wild-type receptors. It appears that the intracellular loops of the D3 receptor are capable of interacting with G proteins, as when these loops are expressed in the D2 receptor, the chimeras inhibit adenylyl cyclase similarly to the wild-type D2 receptor. Our data suggest that the overall conformation of the D3 receptor may be such that it interacts with G proteins only weakly, but when the intracellular loops are expressed in another context or the D3 receptor structure is altered by the introduction of D2 receptor sequence, this constraint may be lifted.


Subject(s)
Adenylyl Cyclase Inhibitors , Receptors, Dopamine D2/physiology , Adenylyl Cyclases/metabolism , Cell Line/chemistry , Cell Line/enzymology , Cyclic AMP/antagonists & inhibitors , Humans , Kidney/cytology , Protein Conformation , Receptors, Dopamine D2/chemistry , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/physiology
15.
Cell Transplant ; 5(1): 77-91, 1996.
Article in English | MEDLINE | ID: mdl-8665080

ABSTRACT

The ability to replace damaged myocardial tissue with new striated muscle would constitute a major advance in the treatment of diseases that irreversibly injure cardiac muscle cells. The creation of focal grafts of skeletal muscle has been reported following the intramural injection of skeletal myoblasts into both normal and injured myocardium. The goals of this study were to determine whether skeletal myoblast-derived cells can be engrafted into the murine heart following arterial delivery. The murine heart was seeded with genetically labeled C2C12 myoblasts introduced into the arterial circulation of the heart via a transventricular injection. A transventricular injection provided access to the coronary and systemic circulations. Implanted cells were characterized using histochemical staining for beta-galactosidase, immunofluorescent staining for muscle-specific antigens, and electron microscopy. Initially the injected cells were observed entrapped in myocardial capillaries. One week after injection myoblasts were present in the myocardial interstitium and were largely absent from the myocardial capillary bed. Implanted cells underwent myogenic development, characterized by the expression of a fast-twitch skeletal muscle sarcoendoplasmic reticulum calcium ATPase (SERCA1) and formation of myofilaments. Four months following injection myoblast-derived cells began to express a slow-twitch/cardiac protein, phospholamban, that is normally not expressed by C2C12 cells in vitro. Most surprisingly, regions of close apposition between LacZ labeled cells and native cardiomyocytes contained structures that resembled desmosomes, fascia adherens junctions, and gap junctions. The cardiac gap junction protein, connexin43, was localized to some of the interfaces between implanted cells and cardiomyocytes. Collectively, these findings suggest that arterially delivered myoblasts can be engrafted into the heart, and that prolonged residence in the myocardium may alter the phenotype of these skeletal muscle-derived cells. Further studies are necessary to determine whether arterial delivery of skeletal myoblasts can be developed as treatment for myocardial dysfunction.


Subject(s)
Graft Survival , Heart , Muscle, Skeletal/transplantation , Animals , Biomarkers , Calcium-Binding Proteins/analysis , Calcium-Binding Proteins/biosynthesis , Cell Line , Connexin 43/analysis , Connexin 43/biosynthesis , Escherichia coli , Male , Mice , Mice, Inbred C3H , Microscopy, Electron , Muscle Fibers, Skeletal/ultrastructure , Muscle, Skeletal/cytology , Muscle, Skeletal/physiology , Recombinant Proteins/analysis , Recombinant Proteins/biosynthesis , Time Factors , Transfection , Transplantation, Heterotopic/methods , Transplantation, Heterotopic/physiology , beta-Galactosidase/analysis , beta-Galactosidase/biosynthesis
16.
Neuropharmacology ; 35(11): 1503-19, 1996.
Article in English | MEDLINE | ID: mdl-9025098

ABSTRACT

In the central nervous system (CNS), dopamine is involved in the control of locomotion, cognition, affect and neuroendocrine secretion. These actions of dopamine are mediated by five different receptor subtypes, which are members of the large G-protein coupled receptor superfamily. The dopamine receptor subtypes are divided into two major subclasses: the D1-like and D2-like receptors, which typically couple to Gs and Gj mediated transduction systems. In the CNS, the various receptor subtypes display specific anatomical distributions, with D1-like receptors being mainly post-synaptic and D2-like receptors being both pre- and post-synaptic. D1 and D2 dopamine receptors, the most abundant subtypes in the CNS, appear to be expressed largely in distinct neurons. Substance P and dynorphin, which are expressed in D1 receptor-containing neurons, as well as pre-proenkephalin in D2 receptor-containing neurons, have been used as monitors of dopaminergic activity in the CNS. Expression of immediate early genes, in particular fos, has also been found to correlate with dopaminergic transmission. Dopamine released from the hypothalamus controls the synthesis and secretion of prolactin from the anterior pituitary via D2 dopamine receptors. As yet none of the dopamine receptor subtypes have been associated with the etiology of psychotic disorders, such as schizophrenia. However, the recent characterization of D3 and D4 receptors which are, interestingly, expressed in areas of the CNS mediating cognition and affect or showing increased affinity for certain neuroleptics, have renewed the interest and hope of finding effective neuroleptics devoid of side effects. Finally, the recent production of genetically-derived animals lacking several of these receptor genes should help elucidate which specific physiological paradigms the receptors mediate.


Subject(s)
Brain/physiology , Receptors, Dopamine/physiology , Animals , Humans
17.
Mol Pharmacol ; 46(2): 352-6, 1994 Aug.
Article in English | MEDLINE | ID: mdl-7915820

ABSTRACT

The dopamine D3 receptor, although structurally similar to the dopamine D2 receptor, has 100-fold higher affinity for agonists such as dopamine and quinpirole, when these receptors are expressed in 293 cells. Additionally, the D3 receptor has generally lower affinity for several antagonists than does the D2 receptor. To determine which regions of the receptor account for these differences, chimeras between D2 and D3 receptors were constructed in which intracellular loops were exchanged between the two receptors. A D2 receptor containing the third intracellular loop (IL3) from the D3 receptor had 10-20-fold higher affinity for dopamine and quinpirole than did the wild-type D2 receptor. Conversely, the D3 receptor containing the IL3 of the D2 receptor had 15-30-fold lower affinity for agonists than did the wild-type D3 receptor. That is, in these chimeras the IL3 shifted agonist affinity in a direction consistent with the agonist affinity of the receptor from which the IL3 was derived. In contrast, antagonist binding was not significantly altered. Chimeras in which the second intracellular loop was switched between the D2 and D3 receptors had essentially unchanged affinity for both agonists and antagonists. The data presented here suggest that structural differences in the IL3 of the D2 and D3 receptors partially account for observed differences in agonist binding to these receptors.


Subject(s)
Receptors, Dopamine D2 , Receptors, Dopamine/metabolism , Amino Acid Sequence , Cells, Cultured , Dopamine/metabolism , Dopamine Agents/metabolism , Ergolines/metabolism , Humans , Interleukin-3/pharmacology , Molecular Sequence Data , Quinpirole , Receptors, Dopamine/genetics , Receptors, Dopamine D3 , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism
18.
Plant J ; 3(1): 111-20, 1993 Jan.
Article in English | MEDLINE | ID: mdl-8401599

ABSTRACT

Genomic and cDNA clones of the anther-specific APG gene from Arabidopsis thaliana and Brassica napus, which encodes a novel proline-rich protein, were isolated and characterized. Southern blotting and Northern analysis of male fertile and cytoplasmic male sterile varieties of B. napus showed that the APG gene is present as a single copy in the Arabidopsis genome, and that the B. napus APG gene is a member of a small anther-specific gene family. Analysis of developmentally staged B. napus flower buds indicated that APG transcript is confined to the anther during the period of microspore development. Reporter gene fusions established that the APG promoter directs expression in a number of cell types in anthers of transformed plants. This expression is consistent with the temporal pattern of mRNA accumulation in B. napus buds and follows a complex developmental pattern. Most significantly, the promoter is active in both sporophytic and gametophytic cell types, with activity of the transgene in each cell type being delineated by various cytological markers.


Subject(s)
Arabidopsis Proteins , Arabidopsis/genetics , Genes, Plant , Plant Proteins/genetics , Pollen/genetics , Amino Acid Sequence , Arabidopsis/physiology , Brassica/genetics , Cloning, Molecular , DNA , Gametogenesis/genetics , Gene Expression , Glucuronidase/genetics , Molecular Sequence Data , Promoter Regions, Genetic , Restriction Mapping , Spores , Transcription, Genetic
19.
J Clin Invest ; 78(5): 1185-92, 1986 Nov.
Article in English | MEDLINE | ID: mdl-3771791

ABSTRACT

Drug-induced triggered arrhythmias in heart muscle involve oscillations of membrane potential known as delayed or early afterdepolarizations (DADs or EADs). We examined the mechanism of DADs and EADs in ferret ventricular muscle. Membrane potential, tension and aequorin luminescence were measured during exposure to elevated [Ca2+]0, strophanthidin and/or isoproterenol (to induce DADs), or cesium chloride (to induce EADs). Ryanodine (10(-9)-10(-6) M), an inhibitor of Ca2+ release from the sarcoplasmic reticulum, rapidly suppressed DADs and triggered arrhythmias. When cytoplasmic Ca2+-buffering capacity was enhanced by loading cells with the Ca2+ chelators BAPTA or quin2, DADs were similarly inhibited, as were contractile force and aequorin luminescence. In contrast to DADs, EADs induced by Cs were not suppressed by ryanodine or by loading with intracellular Ca2+ chelators. The possibility that transsarcolemmal Ca2+ entry might produce EADs was evaluated with highly specific dihydropyridine Ca channel agonists and antagonists. Bay K8644 (100-300 nM) potentiated EADs, whereas nitrendipine (3-20 microM) abolished EADs. We conclude that DADs and DAD-related triggered arrhythmias are activated by an increase in intracellular free Ca2+ concentration, whereas EADs do not require elevated [Ca2+]i but rather arise as a direct consequence of Ca2+ entry through sarcolemmal slow Ca channels.


Subject(s)
Arrhythmias, Cardiac/physiopathology , Carnivora/physiology , Chlorides , Ferrets/physiology , Heart Rate , Heart/physiology , Animals , Cesium/pharmacology , Chelating Agents/pharmacology , Heart Ventricles/drug effects , Heart Ventricles/physiopathology , Isoproterenol/pharmacology , Membrane Potentials/drug effects , Ryanodine/pharmacology , Strophanthidin/pharmacology , Ventricular Function
20.
J Natl Med Assoc ; 71(6): 593-8, 1979 Jun.
Article in English | MEDLINE | ID: mdl-480398

ABSTRACT

The court-ordered sterilization of a normal 18-year-old black female in North Carolina focused attention on the unfortunate impact of eugenic statutes that allow sterilization as a method of social control. The existence of these laws in many states allows misapplication and abuse of authority which, not infrequently, is directed liberally to blacks and other minority groups.Eugenic sterilization is, at this time, a legally accepted form of "medical treatment." The justification of such sterilization is the vague concept that the presumed "mentally deficient" individual is probably a potential parent of socially inadequate offspring who would likewise be socially inadequate.Since there never has been factual substantiation of whether the sterilization of these individuals will diminish the incidence of mental retardation, it is necessary to focus attention on the concept of eugenic sterilization and point out its many fallacies.


Subject(s)
Eugenics , Intellectual Disability/genetics , Sterilization, Reproductive , Adolescent , Female , Genetic Counseling , Humans , Judicial Role , Legislation, Medical , Social Conditions , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...